Nano-Brain Revolution in Alzheimer’s disease: A New Era of Brain Drug Delivery
Keywords:
Alzheimer’s disease, Nanotechnology, Blood–brain barrier, Nanoparticles, Targeted drug delivery, Neurodegeneration, NeurotherapeuticsSynopsis
It is with immense pride and gratitude that I present this edited volume, “Nano-Brain Revolution in Alzheimer’s Disease: A New Era of Brain Drug Delivery.” Alzheimer’s disease (AD), one of the most challenging neurodegenerative disorders, continues to demand innovative solutions that transcend conventional therapeutic approaches. This book brings together insights from researchers, clinicians, and academicians, focusing on the integration of nanotechnology with neurotherapeutics to advance brain-targeted drug delivery and open new horizons in Alzheimer’s management.
The vision behind this work is to highlight how nanocarrier systems can revolutionize treatment strategies for AD by enabling precise, targeted, and efficient drug delivery across the blood–brain barrier. By bridging traditional wisdom with modern nanomedicine, this volume aims to inspire novel therapeutic avenues that are patient-centric and clinically meaningful.
Chapters
-
Understanding Alzheimer’s Disease Pathophysiology and Therapeutic Gaps
-
Nanotechnology in Neuroscience Transforming Alzheimer's Therapy
-
Overcoming the Blood-Brain Barrier (BBB): Role of Nanocarriers in Targeted Drug Delivery
-
Lipid-Based Nanocarriers: Liposomes and solid lipid Nanoparticles for Alzheimer’s diseases Management
-
Polymeric Nanoparticles, Dendrimers, NPs: Versatile Platforms for Sustained Brain Delivery
-
Intra-nasal Nano drug delivery system: a non-invasive gateway to the brain
-
Targeted and Surface-Engineered Nanocarriers: Precision Therapy in Alzheimer’s disease
-
Theranostic Nanoparticles-Dual Function Platform for Diagnosis & Treatment in Alzheimer’s disease
-
Preclinical Evaluation of Nanocarriers: In Vitro, Ex vivo, and In vivo Models
-
Regulatory, Ethical and Current Status (Clinical trials & Patents) in Nano-Brain Drug Delivery
References
Dubois B, Feldman HH, Jacova C, Cummings JL, DeKosky ST, Barberger-Gateau P, et al. Revising the definition of Alzheimer’s disease: a new lexicon. The Lancet Neurology. 2010 Nov 1;9(11):1118–27.
Knopman DS, Amieva H, Petersen RC, Chételat G, Holtzman DM, Hyman BT, et al. Alzheimer disease. Nat Rev Dis Primers. 2021 May 13;7(1):33.
Scheltens P, Blennow K, Breteler MMB, Strooper B de, Frisoni GB, Salloway S, et al. Alzheimer’s disease. The Lancet. 2016 Jul 30;388(10043):505–17.
Scheltens P, De Strooper B, Kivipelto M, Holstege H, Chételat G, Teunissen CE, et al. Alzheimer’s disease. Lancet. 2021 Apr 24;397(10284):1577–90.
Gustavsson AM, van Westen D, Stomrud E, Engström G, Nägga K, Hansson O. Midlife Atherosclerosis and Development of Alzheimer or Vascular Dementia. Ann Neurol. 2020 Jan;87(1):52–62.
Sim J, Li H, Hameed S, Ting SKS. Clinical Manifestations of Early-Onset Dementia With Lewy Bodies Compared With Late-Onset Dementia With Lewy Bodies and Early-Onset Alzheimer Disease. JAMA Neurol. 2022 Jul 1;79(7):702–9.
Leifer BP. Alzheimer’s disease: Seeing the signs early. Journal of the American Association of Nurse Practitioners. 2009 Nov;21(11):588.
Jack CR Jr, Wiste HJ, Therneau TM, Weigand SD, Knopman DS, Mielke MM, et al. Associations of Amyloid, Tau, and Neurodegeneration Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA. 2019 Jun 18;321(23):2316–25.
